Wells Fargo & Company Nuvation Bio Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 78,989 shares of NUVB stock, worth $240,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

78,989

Previous 51,483 53.43%

Holding current value

$240,916

Previous $187,000 22.99%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.58 - $3.69 $70,965 - $101,497	27,506 Added 53.43%	78,989 $230,000
Q1 2024 May 10, 2024	BUY	$1.46 - $3.97 $9,653 - $26,249	6,612 Added 14.74%	51,483 $187,000
Q4 2023 Feb 09, 2024	BUY	$0.96 - $1.53 $8,503 - $13,552	8,858 Added 24.6%	44,871 $67,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $2.1 $24,479 - $40,798	-19,428 Reduced 35.04%	36,013 $48,000
Q2 2023 Aug 15, 2023	BUY	$1.56 - $1.84 $53,980 - $63,669	34,603 Added 166.06%	55,441 $99,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $33,340 - $51,678	20,838 New	20,838 $34,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $298 - $4,157	-1,029 Reduced 69.95%	442 $1,000
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $266,752 - $481,636	-82,331 Reduced 98.24%	1,471 $5,000
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $243,583 - $467,574	-52,953 Reduced 38.72%	83,802 $441,000
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $274,667 - $356,182	35,441 Added 34.98%	136,755 $1.16 Million
Q3 2021 Nov 15, 2021	BUY	$7.78 - $10.0 $374,326 - $481,140	48,114 Added 90.44%	101,314 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $471,077 - $739,826	51,093 Added 2424.92%	53,200 $496,000
Q1 2021 May 13, 2021	BUY	$9.0 - $14.57 $18,963 - $30,698	2,107 New	2,107 $22,000

Others Institutions Holding NUVB

# of Institutions

151

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $663M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Nuvation Bio Inc. Transaction History